CD80 CD86 Antibodies Capable of Binding Specifically to CD80 and CD86

摘要

The present invention relates to a novel antibody to CD80 and CD86 used to prevent or to treat rheumatoid arthritis. According to the present invention, the antibody is is an antibody that specifically combines to CD80n and/or CD86 overexpressed in a cell. According to the present invention, the antibody has very low homology in comparison with a CDR sequence of conventional CD80 and/or CD86 target antibodies. So, the sequence of antibody has uniqueness. According to the present invention, the antibody has equivalent ability to inhibit T-cell activity performance compared with abatacept used in the conventional treatment of rheumatoid arthritis when treated alone and has the remarkably excellent ability to inhibit T-cell activity performance in comparison with the abatacept when treated in combination with the CD80 target antibody and CD86 target antibody. Also, the antibody of the present invention is very effective in the prevention or the treatment of rheumatoid arthritis.